Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 20 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

6 recruiting1 with results

Enrollment Performance

Analytics

N/A
11(64.7%)
Phase 2
3(17.6%)
Early Phase 1
2(11.8%)
Phase 1
1(5.9%)
17Total
N/A(11)
Phase 2(3)
Early Phase 1(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials
NCT07405775Not ApplicableNot Yet Recruiting

SleepFix for Youth: Digital Behavioural Therapy for Insomnia With E-Psychologist Support

Role: lead

NCT07392177Phase 2Not Yet Recruiting

Understanding the Role of the Locus Coeruleus in Insomnia

Role: lead

NCT06686667Not ApplicableCompleted

The Feasibility of Overnight Time Restricted Eating and Impact on Glucose Levels in Shift Workers

Role: lead

NCT05173844Not ApplicableCompleted

Digital Sleep Therapy for Older Adults With Cognitive Impairment

Role: lead

NCT05067569Not ApplicableCompleted

App-delivered Sleep ThERapy for Older Individuals With Insomnia

Role: lead

NCT05846087Not ApplicableCompleted

Mobile App-delivered Sleep Therapy (SleepFix) for Individuals With Chronic Low Back Pain and Insomnia

Role: lead

NCT06567210Not ApplicableRecruiting

The Effects of Insomnia Treatment on Overnight Regulation of Emotional Memories and Risk for Mental Disorders

Role: lead

NCT06823752Phase 2Recruiting

A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.

Role: lead

NCT07006233Not ApplicableRecruiting

A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic Hypersomnia

Role: collaborator

NCT06801379Early Phase 1Recruiting

A Novel Inhaled Formulation of Melatonin to Treat Adults With Insomnia: Pharmacokinetic Study

Role: lead

NCT06802913Early Phase 1Recruiting

A Novel Inhaled Formulation of Melatonin to Treat Adults With Insomnia: Efficacy Study

Role: lead

NCT05606991Not ApplicableEnrolling By Invitation

The Effect of OSA on Brain Waste Clearance

Role: lead

NCT05335083Not ApplicableNot Yet Recruiting

CPAP and Glucose Metabolism in Non-Diabetic OSA Subjects

Role: lead

NCT06110962Recruiting

Detecting Heart Rate, Respiration, and Sleep With the Sleeptracker-AI Under-mattress Monitor

Role: lead

NCT06114901Not ApplicableNot Yet Recruiting

Efficacy of Mobile-delivered Sleep Restriction Therapy for Treatment of Insomnia Disorder: Randomised Controlled Trial

Role: lead

NCT06377332Unknown

Biomarkers of Dementia in Chronic Sleep and Breathing Disorders

Role: lead

NCT05344170Phase 1Completed

Cannabinol Use in Patients With Insomnia Disorder

Role: lead

NCT05253417Phase 2Completed

The CANabidiol Use for RElief of Short Term Insomnia

Role: collaborator

NCT01552031Unknown

Monitoring Chronic Obstructive Pulmonary Disease Patients at Home by a Forced Oscillation Technique Device

Role: collaborator

NCT02570425Not ApplicableCompleted

Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices

Role: collaborator

All 20 trials loaded